• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYBoard
  • MYInsights
  • Strategy & Consulting
  • Contact Us
Select Page

FDA Approves Aphexda Plus Filgrastim for Patients With Multiple Myeloma

by | Sep 11, 2023 | Uncategorized

Source: CureToday articles The FDA has approved Aphexda plus filgrastim for the mobilization of hematopoietic stem cells in patients with multiple myeloma. Read More

Sustained MRD negativity after CAR-T improves outcomes in multiple myeloma

by | Sep 9, 2023 | Uncategorized

Patients with multiple myeloma who exhibited sustained minimal residual disease negativity after treatment with ciltacabtagene autoleucel achieved longer PFS and duration of response, according to study results.All patients with sustained minimal residual disease...

Mezigdomide-dexamethasone combination active in heavily pretreated multiple myeloma

by | Aug 30, 2023 | Uncategorized

The combination of mezigdomide and dexamethasone exhibited activity among patients with heavily pretreated multiple myeloma, according to study results published in The New England Journal of Medicine.“This study represents the culmination of discoveries made over the...

FDA Approval of Elrexfio Represents ‘a Very Hopeful Time’ for Heavily Pretreated Multiple Myeloma

by | Aug 28, 2023 | Uncategorized

Source: CureToday articles Elrexfio has been shown to provide patients with relapsed/refractory multiple myeloma who previously received four or more lines of therapy with a response that may last at least 15 months, an expert explained. Read More

Talvey Giving Patients With Heavily Pretreated Multiple Myeloma ‘a New Lease on Life’

by | Aug 24, 2023 | Uncategorized

Source: CureToday articles The recent FDA approval of Talvey for heavily pretreated multiple myeloma results in an improved response to therapy and a manageable side effect profile. Read More

2023 Myeloma Action Month: The Global Multiple Myeloma Community Comes Together to Raise Awareness

by | Aug 18, 2023 | Uncategorized

Source: CureToday articles Post Content Read More
« Older Entries
Next Entries »

Recent Content

  • Whole genome sequencing and the genetics of extramedullary disease in multiple myeloma
  • Tunneling nanotubes between bone marrow stromal cells support transmitophagy and resistance to apoptosis in myeloma
  • IVIG Supplementation Reduces Infection Risk in Patients With Multiple Myeloma Receiving Teclistamab
  • Combination induces durable responses in advanced multiple myeloma
  • Patient-reported outcome domains in multiple myeloma randomized controlled trials and association with survival outcomes
  • Peroxiredoxin 6 maintains mitochondrial homeostasis and promotes tumor progression through ROS/JNK/p38 MAPK signaling pathway in multiple myeloma
  • Deeper response predicts better outcomes in high-risk-smoldering-myeloma: results of the I-PRISM phase II clinical trial
  • Addition of Elotuzumab to Backbone Treatment Regimens for Multiple Myeloma: An Updated Meta-Analysis of Randomized Clinical Trials
  • Efficacy and safety of chimeric antigen receptor T cells targeting BCMA and GPRC5D in relapsed or refractory multiple myeloma
  • A Year of Resilience: Looking Back After a Myeloma Diagnosis
  • Facebook
  • X
  • Instagram
©2016-2024 MYELOMA360
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT